Janssen reports decline in 2022 net prices as out-of-pocket costs grow
While net prices for Janssen’s commercial drugs have declined for the sixth consecutive year, out-of-pocket costs have continued to rise for some patients, according to the company’s latest US Pricing Transparency Report.
The company provided $39 billion last year in the form of rebates, discounts and fees to commercial health insurers, pharmacy benefit managers and other intermediaries, it said in the report — a more than $5 billion increase compared to 2021. A majority of that, or $11.2 billion, went to commercial payers and PBMs, while 16% (or $6.2 billion) went to the 340B program, 13% ($5.1 billion) went to Medicare and 10% ($3.8 billion) to Medicaid.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters